Coya Therapeutics Business Summary

Coya Therapeutics, Inc. (COYA) is a clinical-stage biotechnology company that generates revenue primarily through strategic licensing agreements, milestone payments, and research partnerships, most notably a multi-indication collaboration with Dr. Reddy’s Laboratories. The company’s business model focuses on the development of proprietary platforms designed to restore regulatory T cell (Treg) function to treat neurodegenerative, autoimmune, and metabolic diseases. Its primary business segments are organized around three therapeutic modalities: Treg-enhancing biologics (led by COYA 302), Treg-derived exosomes (EXO 001), and autologous Treg cell therapies (ALS 001). Coya’s competitive positioning is defined by its dual-mechanism approach that simultaneously boosts anti-inflammatory Treg activity and suppresses pro-inflammatory effector cells, a strategy currently being validated in Phase 2 trials for ALS and FTD. Direct competitors include Gain Therapeutics, Avalo Therapeutics, and Zura Bio, against whom Coya competes by targeting the underlying immune dysfunction of neurodegeneration rather than isolated symptomatic pathways. The leadership team is anchored by Chief Executive Officer Dr. Arun Swaminathan, a former Actinium Pharmaceuticals executive with over 20 years of experience in healthcare strategy and business development. He is supported by President and Chief Medical Officer Dr. Fred Grossman, who brings a pedigree from Roche and Eli Lilly, and CFO/COO David Snyder, who has over 25 years of experience managing public high-growth biotech financials. The company was co-founded by Executive Chairman Dr. Howard Berman, an industry veteran with previous leadership roles at AbbVie and Eli Lilly. Coya’s governance is bolstered by a notable Board of Directors including former U.S. Secretary of Commerce Wilbur Ross, former Bayer Pharma AG CEO Dieter Weinand, and Dr. Ann Lee, the current CTO of Prime Medicine. Major institutional and strategic investors include Greenlight Capital, the company's largest shareholder, and Dr. Reddy’s Laboratories, which recently solidified its commitment with a $10 million strategic investment in January 2026.